WO2004016738A3 - Procede et composition pour traiter et prevenir une infection par le virus de l'hepatite c - Google Patents

Procede et composition pour traiter et prevenir une infection par le virus de l'hepatite c Download PDF

Info

Publication number
WO2004016738A3
WO2004016738A3 PCT/US2003/022956 US0322956W WO2004016738A3 WO 2004016738 A3 WO2004016738 A3 WO 2004016738A3 US 0322956 W US0322956 W US 0322956W WO 2004016738 A3 WO2004016738 A3 WO 2004016738A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
infection
patient
composition
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/022956
Other languages
English (en)
Other versions
WO2004016738A2 (fr
Inventor
Scott Morham
Kenton Zavitz
Adrian Hobden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myriad Genetics Inc
Original Assignee
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc filed Critical Myriad Genetics Inc
Priority to AU2003256678A priority Critical patent/AU2003256678A1/en
Publication of WO2004016738A2 publication Critical patent/WO2004016738A2/fr
Publication of WO2004016738A3 publication Critical patent/WO2004016738A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés pour prévenir et traiter une infection par le virus de l'hépatite C et des symptômes de cette infection. Ces procédés consistent à introduire chez un patient des cellules présentant un phénotype de bourgeonnement modifié du virus de l'hépatite C ou à administrer à un patient des acides nucléiques, des polypeptides et de petits composés organiques afin d'induire la formation de cellules présentant un phénotype de bourgeonnement modifié du virus de l'hépatite C dans le corps de ce patient.
PCT/US2003/022956 2002-07-19 2003-07-21 Procede et composition pour traiter et prevenir une infection par le virus de l'hepatite c Ceased WO2004016738A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003256678A AU2003256678A1 (en) 2002-07-19 2003-07-21 Method and composition for treating and preventing hepatitis c infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39726702P 2002-07-19 2002-07-19
US60/397,267 2002-07-19

Publications (2)

Publication Number Publication Date
WO2004016738A2 WO2004016738A2 (fr) 2004-02-26
WO2004016738A3 true WO2004016738A3 (fr) 2004-06-17

Family

ID=31888187

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/022956 Ceased WO2004016738A2 (fr) 2002-07-19 2003-07-21 Procede et composition pour traiter et prevenir une infection par le virus de l'hepatite c

Country Status (2)

Country Link
AU (1) AU2003256678A1 (fr)
WO (1) WO2004016738A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006011686A1 (fr) * 2004-07-30 2006-02-02 Japan Tobacco Inc. Procédé de recherche par criblage d'un composé empêchant l'infection de cellules par le virus de l'hépatite c (vhc)
KR100734525B1 (ko) * 2005-05-27 2007-07-03 크레아젠 주식회사 인간 및 비근교계 동물에서 세포독성 ｔ 임파구 활성을효과적으로 측정하는 방법
CN100586474C (zh) * 2006-12-28 2010-02-03 北京炎黄麒麟生物技术开发有限公司 药物组合物、试剂盒及其应用
CN108707190B (zh) * 2018-04-18 2021-07-13 中国科学院武汉病毒研究所 猪瘟病毒ns5b蛋白保真度突变体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228576B1 (en) * 1997-12-11 2001-05-08 Smithkline Beecham Corporation Hepatitis C virus NS5B truncated protein and methods thereof to identify antiviral compounds
US6461845B1 (en) * 1995-09-27 2002-10-08 Emory University Recombinant hepatitis C virus RNA replicase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461845B1 (en) * 1995-09-27 2002-10-08 Emory University Recombinant hepatitis C virus RNA replicase
US6228576B1 (en) * 1997-12-11 2001-05-08 Smithkline Beecham Corporation Hepatitis C virus NS5B truncated protein and methods thereof to identify antiviral compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EGGER D. ET AL.: "Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex", J. VIROL., vol. 76, no. 12, June 2002 (2002-06-01), pages 5974 - 5984, XP002973294 *
KOLYKHALOV A.A. ET AL.: "Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo", J. VIROL., vol. 74, no. 4, February 2000 (2000-02-01), pages 2046 - 2051, XP002973293 *

Also Published As

Publication number Publication date
AU2003256678A1 (en) 2004-03-03
WO2004016738A2 (fr) 2004-02-26
AU2003256678A8 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
WO2002058638A3 (fr) Medicaments a base de serpine pour le traitement de l'infection par vih et utilisation de ceux-ci
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
WO2007001406A3 (fr) Composes macrocycliques contenant un aryle
WO2004043339A3 (fr) Inhibiteurs du virus de l'hepatite c a base de cycloalkyle p1' substitue
WO2005037214A3 (fr) Acylsulfonamides et acides carboxyliques macrocycliques utilises en tant qu'inhibiteurs de la replication du virus de l'hepatite c
WO2005021707A3 (fr) Compositions vaccinales d'adn contre le syndrome respiratoire aigu severe et leurs procedes d'utilisation
EP1441720B8 (fr) Inhibiteurs de la serine protease, en particulier de la protease ns3-ns4a du virus de l'hepatite c, integrant un systeme de cycles accoles
NO20100093L (no) Peptidomimetiske protease-inhibitorer
WO2004092405A3 (fr) Gene d'hemochromatose juvenile (hfe2a), produits d'expression et leurs utilisations
WO2003089619A3 (fr) Cellules souches placentaires et utilisations
WO2002060926A3 (fr) Inhibiteurs du virus de l'hepatite c
WO2005035525A3 (fr) Inhibiteurs des serines proteases, en particulier de la protease ns3-ns4a du virus de l'hepatite c (vhc)
PT1782825E (pt) Tratamento de doenças de armazenanto de glicogénio tipo ii
WO2005063734A3 (fr) Thiophenes substitues
WO2005046583A3 (fr) Facteur fviii modifie presentant une immunogenicite reduite par mutagenese d'epitopes a2 et c2
EP1505990A4 (fr) Methodes de traitement de l'hepatite
WO2005002526A3 (fr) Procedes et compositions pour le traitement d'infections virales
NO20071912L (no) Donepezilsalter egnet for fremstilling av farmasoytiske sammensetninger.
WO2001023421A3 (fr) Compositions des proteines du stress et procedes de prevention et de traitement d'un cancer et d'une maladie infectieuse
WO2003030886A3 (fr) Allylamides utilises dans le traitement de la maladie d'alzheimer
WO2003015708A8 (fr) Traitement de l'infection par le vih et composition a cet effet
UA91677C2 (ru) Макроциклические соединения как ингибиторы вирусной репликации
WO2003059262A3 (fr) Methode et composition de traitement et de prevention d'infections par vih et du sida
WO2005094554A3 (fr) Agents, methodes et traitements therapeutiques
WO2004009032A3 (fr) Methode et composition utilisees pour traiter et prevenir l'infection par le virus de l'hepatite b et les symptomes associes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP